Diclofenac epolamine metered dose spray film - Virpax Pharmaceuticals
Alternative Names: Diclofenac epolamine - Virpax Pharmaceuticals; DSF-100; Epoladerm; OSF-200Latest Information Update: 21 May 2024
At a glance
- Originator Virpax Pharmaceuticals
- Developer MedPharm; Virpax Pharmaceuticals
- Class Analgesics; Aniline compounds; Antirheumatics; Benzene derivatives; Chlorinated hydrocarbons; Nonsteroidal anti-inflammatories; Phenylacetates; Pyrrolidines; Small molecules
- Mechanism of Action Cyclooxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Musculoskeletal pain; Osteoarthritis
Most Recent Events
- 16 May 2024 Preclinical development is ongoing in USA for Musculoskeletal pain and Osteoarthritis
- 28 Apr 2024 No recent reports of development identified for preclinical development in Osteoarthritis in USA (Topical, Spray)
- 10 Aug 2023 Virpax pharmaceuticals files for provisional patent protection with United States Patent and Trademark Office (‘USPTO’) for NSAID Formulation and Method related to diclofenac epolamine metered dose spray film in the USA